Genitourinary Radiology: Page 56

Endorectal MRI provides predictive biomarker for prostate cancer patients
By Wayne Forrest
Monday, November 28 | 10:40 a.m.-10:50 a.m. | SSC06-02 | Room E353BEndorectal MRI can serve as a predictive biomarker for biochemical relapse in patients undergoing combination brachytherapy and intensity-modulated radiation therapy, according to a new study by researchers at Memorial Sloan-Kettering Cancer Center.
November 14, 2011
Real-time tissue elastography helps assess intratesticular lesions
By Erik L. Ridley
Friday, December 2 | 11:20 a.m.-11:30 a.m. | SST08-06 | Room E351In this Friday session, a U.K. team will show how real-time tissue elastography can increase operator confidence and influence patient management for evaluating intratesticular lesions.
November 13, 2011
CEUS helps detect renal cell carcinoma
By Erik L. Ridley
Sunday, November 27 | 11:55 a.m.-12:05 p.m. | SSA10-08 | Room E353BContrast-enhanced ultrasound (CEUS) can differentiate between benign and malignant renal masses, according to this study from a Canadian research team.
November 13, 2011
CEUS perfusion imaging boosts prostate cancer detection
By Erik L. Ridley
Sunday, November 27 | 11:35 a.m.-11:45 a.m. | SSA21-06 | Room S504ABA contrast-enhanced ultrasound (CEUS) perfusion imaging technique could improve lesion detection in prostate peripheral zone tissue, according to a research initiative led by a contrast developer.
November 13, 2011
Choline-PET/CT in recurrent prostate cancer cases could alter therapy
By Wayne Forrest
Tuesday, November 29 | 11:50 a.m.-12:00 p.m. | SSG12-09 | Room S505ABCholine-PET/CT can greatly affect therapy management for recurrent prostate cancer patients and should be considered for restaging, according to a new study by Swiss researchers.
November 7, 2011
Novel molecular imaging technique could help prostate cancer patients
By Wayne Forrest
Monday, November 28 | 11:20 a.m.-11:30 a.m. | SSC09-06 | Room S504CDIn this paper presentation, Dutch researchers will show early promising results for two novel molecular imaging techniques to detect and manage lymph node metastases in prostate cancer patients.
November 7, 2011
IsoRay receives MD Anderson order
By AuntMinnie.com staff writers
Medical isotope developer IsoRay Medical said that MD Anderson Cancer Center at the University of Texas has begun ordering its cesium-131 brachytherapy seeds.
October 9, 2011
Varian touts prostate cancer study at ASTRO
By AuntMinnie.com staff writers
Radiation therapy developer Varian Medical Systems is highlighting early results from a prospective phase II trial showing that patients with low-risk prostate cancer who underwent stereotactic body radiation therapy experienced minimal toxicities.
October 4, 2011
ASTRO: IMRT produces less rectal toxicity in prostate cancer
By Cynthia E. Keen
Intensity-modulated radiation therapy (IMRT) causes fewer bowel and rectal toxicities than 3D conformal radiation therapy, according to study findings to be presented October 3 at the plenary session of the American Society for Radiation Oncology (ASTRO) annual meeting.
September 27, 2011
Hypofractionated RT works for prostate cancer
By AuntMinnie.com staff writers
A hypofractionated course of radiation therapy is as effective as conventional radiation therapy in reducing intermediate- to high-risk prostate cancer recurrence, according to five-year outcome results of a clinical trial to be presented at next week's American Society for Radiation Oncology annual meeting.
September 26, 2011
Early MRI before surgery predicts rectal cancer survival
By Wayne Forrest
An MRI scan after initial chemotherapy and before surgery may predict long-term outcome for patients with advanced rectal cancer and identify individuals who could benefit from more aggressive therapy prior to surgery, according to a study published online August 29 in the Journal of Clinical Oncology.
August 30, 2011
Calypso co-sponsors prostate cancer fundraiser
By AuntMinnie.com staff writers
Electromagnetic localization technology developer Calypso Medical Technologies is partnering with Zero, a nonprofit Washington, DC-based organization to end prostate cancer, to co-sponsor a series of fundraising 5K and 10K races in five cities.
August 16, 2011
Previous Page
Page 56 of 96
Next Page